Grifols and Mondragon sign technology collaboration agreement

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the production of plasma-derived medicines, and Mondragon, a worldwide leader in work cooperation and one of Spain’s most relevant business groups, today announced an agreement to jointly develop healthcare sector-related automation, robotics and instrumentation as well as other technologies and infrastructure.

The agreement also includes training and talent collaborations linked to the university of the Basque industrial group.

A Joint Action Committee comprised of members from both companies will identify and prioritize initial projects over the next few months. 

“Grifols is exceptionally pleased to collaborate with a highly renown technology and industrial leader such as the Mondragon group. The agreement represents an opportunity to jointly develop innovative technology solutions for the medical and pharmaceutical sectors, particularly projects related to instrumentation and robotics, which are constantly changing,” said Victor Grifols Deu and Raimon Grifols, co-CEOs of Grifols.

“For Mondragon it’s enormously satisfying to sign this collaboration agreement with Grifols after many years of a positive relationship. The framework agreement is designed to drive innovation and new businesses in strategic areas such as health,” said Iñigo Ucin, president of Mondragon.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909, committed to improving the health and well-being of people around the world. Its four divisions - Bioscience, Diagnostic, Hospital and Bio Supplies - develop, produce and market innovative solutions and services in more than 100 countries.

As pioneers in the field of the plasma science, Grifols is one of the largest plasma companies, with a growing network of donation centers worldwide. It develops this plasma into essential medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation through transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 22,000 employees in 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).